In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
about
Fetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor use in human and nonhuman primate pregnancyInfant peripheral blood repetitive element hypomethylation associated with antiretroviral therapy in uteroSurveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infantsAntiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIVBirth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs)Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age.Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothersSubstance use in HIV-Infected women during pregnancy: self-report versus meconium analysis.Associations between use of crack cocaine and HIV-1 disease progression: research findings and implications for mother-to-infant transmission.In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected childrenMutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants.Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study).Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothersPharmacotherapy of pediatric HIV infectionZidovudine use in pregnancy and congenital malformations.Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.Stimulant Medications and Cognition, Behavior and Quality of Life in Children and Youth with HIV.High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothersGrowth and body composition of uninfected children exposed to human immunodeficiency virus: comparison with a contemporary cohort and United States National StandardsLaboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.The Use of the Medical Dictionary for Regulatory Activities in the Identification of Mitochondrial Dysfunction in HIV-Infected Children.Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.What is needed to eliminate new pediatric HIV infections: the contribution of model-based analyses.Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapyEffects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress.A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.Antiretroviral Treatment in HIV-1-Positive Mothers: Neurological Implications in Virus-Free ChildrenAntiretroviral use during pregnancy for treatment or prophylaxis.
P2860
Q28088783-305077A5-99EA-4656-BE3F-E6A8DE8CA50CQ28392255-4B8CA609-F117-4C94-AF1A-E13933FC6C52Q30244368-CCC336AE-F5CB-4874-870C-04ED701279FFQ33747993-8E386FCB-12CC-42B3-9FB8-B89D6CBBC439Q33897042-DC7F7B1D-FFE5-41DF-AFE9-A222BB26D767Q33996797-1436B027-C13A-48F2-8540-71E2B30C3D08Q34036150-D94E57D6-CE6C-491B-8FBB-5AD231D2FA47Q34170220-5E1EC6D9-C45F-4D85-AE96-72D17D03AFB6Q34181048-3EFE0952-1278-48A6-8CEC-729061B5873EQ34200645-2FC4B3FB-1F4B-47F6-AAE3-9EFB959585B4Q34440361-D12A511D-3545-47C3-9ED7-9CA2D02B2BC0Q34881120-D06EC253-A8B1-4F13-A77A-3A4F51CD4A13Q34992602-C35FD05A-AFC1-4BE5-886A-E2CF03984126Q35000633-226DD7F5-613B-4967-86B8-32D532E6C1B7Q35075011-E46BA70A-1ECA-4602-B621-E9095759889EQ35173620-BEA95E9B-F2B3-4FB9-A287-B4EBF59CB7B1Q35327135-E0FFCAA3-046D-41D3-AB56-138F40C95C4BQ35620778-688DFC9A-83AA-427D-B408-A86F559101B0Q35626381-666E88A7-A5BE-418B-B8BD-A73FB8B1C4CDQ35924264-F42ECD1C-58CC-44DC-A9A8-FBA5FD6B9896Q35960706-2A4CE684-30A4-4265-A221-18653667EC82Q36077016-5067F2B1-DE1C-4F9D-9204-BC09E405A0B4Q36301325-584225E0-A4F6-4996-8545-609013733834Q36379162-F0DB1BB8-4177-4E75-808D-CC3A4E196A11Q36438846-AA5A8654-706B-420A-A87D-22918B230407Q36443762-160C8F95-07E6-4295-B9D3-79C628FC34E8Q36744874-F585BD08-3F82-41E3-A130-017A13FB775BQ36809068-787FC515-01EC-43DA-82B0-6129E7FD6CD2Q36851168-695961AD-CE52-4205-88C2-56B1EE2A4D7BQ36870864-12CFD084-152B-4B80-A27F-F7F89F0A4D03Q36929688-08806313-4E30-4DDD-B90D-C4FFCDD2C2EAQ37045192-D2E5FDFB-D7F5-4570-A1C7-3F3860FB4C5FQ37148266-B0D95777-205D-47E4-BF29-8D1E6AC742C0Q37238095-A508FA50-618D-4F06-B4FC-19172BBFE898Q37422499-04A98808-684D-40E8-8E33-D6792AF45E7DQ37492507-4C549FD3-7715-40D4-AF83-279C39B1C6DAQ37552456-3AC7BA06-7F5B-4E34-A816-B38A45580CFDQ37588728-EB405C52-F6B5-400A-AA5D-5DF18B1ECAAEQ37691000-099053DC-46E5-4939-B60D-FF25FC30BCCCQ37870932-AABCD32B-4E32-42BC-9EDA-DB955745F766
P2860
In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In utero nucleoside reverse tr ...... on in HIV-uninfected children.
@ast
In utero nucleoside reverse tr ...... on in HIV-uninfected children.
@en
type
label
In utero nucleoside reverse tr ...... on in HIV-uninfected children.
@ast
In utero nucleoside reverse tr ...... on in HIV-uninfected children.
@en
prefLabel
In utero nucleoside reverse tr ...... on in HIV-uninfected children.
@ast
In utero nucleoside reverse tr ...... on in HIV-uninfected children.
@en
P2093
P1433
P1476
In utero nucleoside reverse tr ...... on in HIV-uninfected children.
@en
P2093
George R Seage
James Oleske
Marilyn J Crain
Mark J Abzug
Michael Brady
Michael D Hughes
Nathalie Ylitalo
Patrick Jean-Philippe
Russell Van Dyke
P304
P356
10.1097/QAD.0B013E3280D5A786
P407
P577
2007-05-01T00:00:00Z